LAE 103
Alternative Names: LAE-103Latest Information Update: 29 Apr 2024
At a glance
- Originator Laekna Therapeutics
- Class Antibodies
- Mechanism of Action Type II-B activin receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Muscular atrophy